

DAFTAR PUSTAKA

- Abib, E., Junior and Duarte, L.F. 2010, 'Comparative biological availability of clopidogrel formulation in healthy volunteers after a single dose administration', *Journal of Bioequivalence & Bioavailability*, vol. 2, no. 2, pp. 45-49, DOI:10.4172/jbb.1000029.
- Andreeva, A.V. and Filippov, E.V. 2024, 'Comparison of effectiveness of branded and generic clopidogrel in patients with ST-elevation acute coronary syndrome on electrocardiogram', *I P Pavlov Russian Medical Biological Herald*, vol. 32, no. 4, pp. 549–556, DOI:10.17816/pavlovj340920.
- Amsterdam, E.A., Wenger, N.K., Brindis, R.G., Casey, D.E., Ganiats, T.G., Holmes, D.R., Jaffe, A.S., Jneid, H., Kelly, R.F., Kontos, M.C., Levine, G.N., Liebson, P.R., Mukherjee, D., Peterson, E.D., Sabatine, M.S., Smalling, R.W., Zieman, S.J. and Members, A., 2014, '2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes', *Circulation*, 130(25), pp.e344–e426. DOI: 10.1161/CIR.0000000000000134
- Ai, M., Chen, Y., Kuo, C., & Chang, W, 2024, 'A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients', *Frontiers in Cardiovascular Medicine*, 11. DOI:10.3389/fcvm.2024.1385318.
- Brandt, J.T., Close, S.L., Iturria, S.J., Payne, C.D., Farid, N.A., Ernest, C.S., Lachno, D.R., Salazar, D., & Winters, K.J, 2007, 'Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel', *Journal of Thrombosis and Haemostasis*, vol. 5, no. 12, pp. 2429–2436, DOI: 10.1111/j.1538-7836.2007.02775.x.
- Brown, J.C., Gerhardt, T.E. and Kwon, E., 2023, 'Risk Factors for Coronary Artery Disease', *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK554410/>
- Benziger, C.P. dkk., 2024. 'Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in male and female patients: a secondary analysis of the ADAPTABLE randomized clinical trial', *JAMA Cardiology*, vol. 9, no. 9, pp. 808–816. <https://doi.org/10.1001/jamacardio.2024.1712>

- Bouziana, S.D. & Tziomalos, K., 2015, 'Clinical relevance of clopidogrel-proton pump inhibitors interaction', *World Journal of Gastrointestinal Pharmacology and Therapeutics*, vol. 6, no. 2, pp. 17–21, DOI: 10.4292/wjgpt.v6.i2.17.
- Brown, S.-A., & Pereira, N., 2018, 'Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in Precision Cardiovascular Medicine', *Journal of Personalized Medicine*, vol. 8, no. 1, pp. 8, DOI:10.3390/jpm8010008.
- Caldeira, D., Fernandes, R.M., Costa, J., David, C., Sampaio, C. & Ferreira, J.J., 2013, 'Branded Versus Generic Clopidogrel in Cardiovascular Diseases: A Systematic Review', *Journal of Cardiovascular Pharmacology*, 61(4), pp.277–282.
- Carzen, C., 2018, 'Antiplatelet therapy in acute coronary syndrome: Beyond aspirin and clopidogrel', *American Journal of Cardiovascular Drugs*, DOI: 10.1136/heartjnl-2012-302299.
- Campbell, K.L., Cohn, J.R. and Savage, M.P., 2010, 'Clopidogrel hypersensitivity: clinical challenges and options for management.', Division of Cardiology Faculty Papers. Paper 13. <https://jdc.jefferson.edu/cardiologyfp/13>
- Camici, P.G. & Crea, F., 2007, 'Coronary Microvascular Dysfunction', *The New England Journal of Medicine*, vol. 356, no. 8, pp. 830–840, DOI: 10.1056/NEJMr061889
- Chan, E.W., Wong, I.C.K., Yau, W.P., & Man, K.K.C., 2023, 'Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention of cardiovascular disease: A systematic review and meta-analysis', *Clinical and Translational Science*, 16(2), 287–298.
- Chen, X., Xu, J., Chen, S., Dong, Q., & Dong, Y., 2022, 'Dual antiplatelet therapy with ticagrelor may increase the risk of all bleeding events in patients with minor strokes or high risk Tias: A meta-analysis', *Stroke and Vascular Neurology*, vol. 7, no. 4, pp. 271–275, DOI:10.1136/svn-2021-001423
- Chunsangchan, M. et al., 2017 'Bioequivalence and pharmacokinetic/pharmacodynamic correlation of clopidogrel in healthy Thai subjects', *International Journal of Clinical Pharmacology and Therapeutics*, vol. 55, no. 12, pp. 915–922, DOI:10.5414/cp203054.
- Chow, S.C., 2014, 'Bioavailability and Bioequivalence in Drug Development. Wiley interdisciplinary reviews', *Computational statistics*, vol. 6, no. 4, pp. 304–312, DOI:10.1002/wics.1310

- Cheema, A.N., Mohammad, A., Hong, T., Jakubovic, H.R., Parmar, G.S., Sharieff, W., Garvey, M.B., Kutryk, M.J.B., Fam, N.P., Graham, J.J. & Chisholm, R.J., 2011, 'Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation', *Journal of the American College of Cardiology*, vol. 58, no. 14, pp. 1445–1454. DOI: 10.1016/j.jacc.2011.06.040
- Dunne, S. S., & Dunne, C. P., 2015, 'What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs', *BMC medicine*, vol. 13, no. 1, pp 173.
- Dorado, A.P., 2025, 'Dual antiplatelet vs monotherapy as secondary prevention for myocardial infarction in coronary artery disease', The PA Department *Journal of Medical Science*, Gardner-Webb University, Master of Science (MS) Capstone.
- DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D. and Ellingrod, V., 2020, *Pharmacotherapy: A pathophysiologic approach*, 11th ed., New York: McGraw-Hill Education.
- Ference, B.A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K.K., Mewada, A., Kahn, J., Afonso, L., Williams, K.A. and Flack, J.M., 2012, 'Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis', *Journal of the American College of Cardiology*, vol. 60, no. 25, pp. 2631–2639. DOI: 10.1016/j.jacc.2012.09.017
- Gladstone, D.J. et al., 2015, 'Atrial premature beats predict atrial fibrillation in cryptogenic stroke', *Stroke*, vol. 46, no. 4, pp. 936–941, DOI:10.1161/strokeaha.115.008714.
- Hartayu, T.S., & Setyaningsih, D, 2017, 'The effectiveness of clopidogrel as an antithrombotic compared to ticlopidine and aspirin (meta-analysis)', *Journal of Pharmaceutical Sciences and Community*, vol. 14, no. 1, pp. 65–73.
- Holmes, D.R., Dehmer, G.J., Kaul, S., Leifer, D., O’Gara, P.T., & Stein, C.M, 2010, 'ACCF/AHA clopidogrel clinical alert: Approaches to the FDA “Boxed warning”', *Circulation*, vol. 122, no. 5, pp. 537–557, DOI:10.1161/cir.0b013e3181ee08ed
- Ho, P.M., Maddox, T.M., Wang, L., Fihn, S.D., Jesse, R.L., Peterson, E.D. & Rumsfeld, J.S., 2009, 'Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome', *JAMA*, 301(9), pp.937–944.

- Ho, P.M., Peterson, E.D., Wang, L., Magid, D.J., Fihn, S.D., Larsen, G.C., Jesse, R.A. & Rumsfeld, J.S., 2008. 'Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome', *JAMA*, vol. 299, no. 5, pp. 532–539. DOI: 10.1001/jama.299.5.532
- Hoshino, H., Toyoda, K., Omae, K., Ishida, N., Uchiyama, S., Kimura, K., Sakai, N., Okada, Y., Tanaka, K., Origasa, H., Naritomi, H., Houkin, K., Yamaguchi, K., Isobe, M., Minematsu, K., Matsumoto, M., Tominaga, T., Tomimoto, H., Terayama, Y., ... Yamaguchi, T., 2021, 'Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: Subanalysis of the csps.com trial' *Stroke*, vol. 52, no. 11, pp. 3430–3439, DOI: 10.1161/strokeaha.121.034378
- Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.P., Crea, F., Goudevenos, J.A., Halvorsen, S., Hindricks, G., Kastrati, A., Lenzen, M.J., Prescott, E., Roffi, M., Valgimigli, M., Vranckx, P. and Widimsky, P., 2018, '2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation', *European Heart Journal*, 39(2), pp.119–177. DOI:10.1093/eurheartj/ehx393
- Kesselheim, A.S., Avorn, J., & Sarpatwari, A., 2016, 'The high cost of prescription drugs in the United States: origins and prospects for reform', *JAMA*, vol. 316, no. 8, pp. 858-871.
- Kaski, J.C., 2004, 'Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X)', *Circulation*, vol. 109, no. 5, pp. 568–572. DOI: 10.1161/01.CIR.0000116601.58103.62
- Ko, D.T., Krumholz, H.M., Tu, J.V., Austin, P.C., Stukel, T.A., Koh, M., Chong, A., de Melo, J.F., & Jackevicius, C.A., 2018, 'Clinical outcomes of Plavix and generic clopidogrel for patients hospitalized with an acute coronary syndrome', *Circulation: Cardiovascular Quality and Outcomes*, vol. 11, no. 3, pp. e004194, DOI: 10.1161/CIRCOUTCOMES.117.004194
- Lemeshow, S., & World Health Organization (Eds.), 1990, *Adequacy of sample size in health studies*, Wiley, USA.
- Libby, P., Ridker, P.M., & Maseri, A., 2002, 'Inflammation and atherosclerosis', *Circulation*, vol. 105, no. 9, pp. 1135–1143. DOI: 10.1161/hc0902.104353
- Luo, B., Yu, F., Ge, W. & Yang, X., 2023, 'Can generic medications be a safe and effective alternative to brand-name drugs for cardiovascular disease treatment? A systematic review and meta-analysis', *Reviews in Cardiovascular Medicine*, 26(3), pp.321–334.

- Ma, T.K., Lam, Y.Y., Tan, V.P., & Yan, B.P, 2011, ‘Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?’, *British journal of clinical pharmacology*, vol. 72, no. 4, pp. 697–706, DOI:10.1111/j.1365-2125.2011.03949.x
- Masenga, S. K. & Kirabo, A., 2023, ‘Hypertensive heart disease: risk factors, complications and mechanisms’, *frontiers in cardiovascular medicine*, vol. 10, pp. 1205475.
- Mendelson, S.J. & Prabhakaran, S., 2021, ‘Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review’, *JAMA*, vol. 325, no. 11, pp. 1088-1098.
- Neubauer, H., Günesdogan, B., Hanefeld, C., Spiecker, M., & Mügge, A., 2003, ‘Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study’, *European Journal of Internal Medicine*, 24, pp.1744–1749, DOI: 10.1016/S0195-668X(03)00442-1
- Neumann, F.J dkk., ‘2018 ESC/EACTS Guidelines on myocardial revascularization. *European Heart Journal*’, 40(2), pp.87–165. <https://doi.org/10.1093/eurheartj/ehy394>
- Nguyen, K.A., Eadon, M.T., Yoo, R., Milway, E., Kenneally, A., Fekete, K., Oh, H., Duong, K., Whipple, E.C. and Schleyer, T.K, 2020, ‘Risk factors for bleeding and clinical effectiveness associated with clopidogrel therapy: A comprehensive meta-analysis’, *Clinical and Translational Science*, 14(2), pp. 645–655. doi:10.1111/cts.12926.
- Park, J.S., Cha, K.S., Lee, H.W., Oh, J.H., Choi, J.H., Lee, H.C., Hong, T.J., Kim, H.S., 2016, ‘Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention’, DOI: 10.1007/s00380-016-0927-6
- Patel, S., Kim, H.H. & Yancy, C.W., 2020, ‘Management of coronary artery disease in patients with comorbid conditions: impact on therapy and outcomes’, *Cardiology Clinics*, vol. 38, no. 4, pp. 561–574.
- Patti, G., Micieli, G., Cimminiello, C., & Bolognese, L, 2020, ‘The role of clopidogrel in 2020: A reappraisal’, *Cardiology and Therapy*, vol. 9, no. 1, pp. 5–20.
- Patti, G., Nusca, A., Mangiacapra, F., Gatto, L., D’Ambrosio, A., Di Sciascio, G., 2008, ‘Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention: Results from the ARMYDA-PRO study’, *Journal of the American College of Cardiology*, vol 52, no. 14, pp. 1128–1133.

- Badan Pengawas Obat Dan Makanan & Sampurno, 2005, 'Peraturan Kepala Badan Pengawas Obat Dan Makanan Republik Indonesia Nomor HK.00.05.3.1818 Tentang Pedoman Uji Bioekivalensi'.
- PERKI (Perhimpunan Dokter Kardiovaskular Indonesia), 2024, Pedoman Tatalaksana Sindrom Koroner Akut. PERKI, Jakarta.
- Plavix [clopidogrel bisulfate] prescribing information, 2018, Plavix, viewed 01 July 2025, (<https://www.plavix.com>)
- Raju, K.D., 2022, 'Patent linkages and its impact on access to medicines: challenges, opportunities for developing countries', in Springer eBooks, pp. 329–369, DOI:10.1007/978-3-030-83114-1_12.
- Roth, G.A., Johnson, C., Abajobir, A., dkk, 2017, 'Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015', Journal of the American College of Cardiology, vol. 70, no. 1, pp. 1-25.
- Rodgers, J.L., Jones, J., Bolleddu, S.I., Vanthenapalli, S., Rodgers, L.E., Shah, K., Karia, K., & Panguluri, S.K., 2019, 'Cardiovascular risks associated with gender and aging', Journal of Cardiovascular Development and Disease, 6(2), p.19. <https://doi.org/10.3390/jcdd6020019>
- Rajendran, N., Sambandan, G., Rafi, P.A. and Partheeban, V., 2025, 'Bioequivalence study of two formulations of clopidogrel tablets under fasting conditions in healthy adult subjects', Saudi Journal of Medical and Pharmaceutical Sciences, vol. 11, no. 1, pp. --. DOI: 10.36348/sjmps.2025.v11i01.006
- Ryczkowska, M., Pawlak, A. & Orzechowska, M., 2023, 'Gender differences in coronary artery disease: from pathophysiology to clinical practice', European Heart Journal – Cardiovascular Pharmacotherapy, vol. 9, no. 3, pp. 176–183.
- Ryczkowska, M., Wróbel, M., Ścibisz, M., & Łopatyński, P, 2023, 'Gender differences in cardiovascular disease prevalence and treatment outcomes', Cardiology Review, vol. 31, no. 4, pp. 201-215, DOI:10.1097/CRD.0000000000000413
- Serebruany, V. L., Hall, T. S., Atar, D., Agewall, S., Hyun Kim, M., Geudelin, B., Lomakin, N., & Marciniak, T.A, 2018, 'Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System', European Heart Journal - Cardiovascular Pharmacotherapy, vol. 5, no. 4, pp. 210–215, DOI:10.1093/ehjcvp/pvy035

- Serebruany, V.L., Kuliczkowski, W. & Atar, D., 2019, 'Plavix® versus generic clopidogrel: is there a reason for clinical concern?' *Cardiology Journal*, vol. 26, no. 6, pp. 584–589.
- Setiawati, A., 2011, 'The Importance of Bioequivalence Study: Focus on Clopidogrel', *Medical Journal of Indonesia*, vol. 20, no. 2, pp. 149-153.
- Singh, M., Arora, R.R., & Thapa, B., 2018, 'Clopidogrel pharmacogenetics and its clinical implications', DOI: 10.1097/MJT.0b013e3181afbf62
- Sheng, J., Li, Y., Zhang, Y. & Wang, X., 2022, 'Real-world evaluation of generic clopidogrel bioequivalence and its clinical implications', *Frontiers in Pharmacology*, vol. 13, pp. 90517
- Singh, M., Peterson, E.D. & Roe, M.T., 2023, 'Aging and coronary artery disease: clinical perspectives and implications', *Journal of the American Geriatrics Society*, vol. 71, no. 4, pp. 1082–1090.
- Tyson, R.J., Park, C.C., Powell, J.R., Patterson, J.H., Weiner, D., Watkins, P. B., & Gonzalez, D., 2020, 'Precision dosing priority criteria: Drug, disease, and patient population variables', *Frontiers in Pharmacology*, vol. 11, pp. 420, DOI:10.3389/fphar.2020.00420
- Thygesen, K., Alpert, J.S., Jaffe, A.S., Chaitman, B.R., Bax, J.J., Morrow, D.A. and White, H.D., 2019, 'Fourth Universal Definition of Myocardial Infarction (2018)', *Circulation*, 138(20), pp.e618–e651, DOI: 10.1161/CIR.0000000000000617
- Udell, J.A., Braunwald, E., Antman, E.M., Murphy, S.A., Montalescot, G., & Wiviott, S.D., 2014, 'Prasugrel versus clopidogrel in patients with st-segment elevation myocardial infarction according to timing of percutaneous coronary intervention', *JACC: Cardiovascular Interventions*, vol. 7, no. 6, pp. 604–612, DOI:10.1016/j.jcin.2014.01.160
- Vincent Rajkumar S, 2020, 'The high cost of prescription drugs: causes and solutions', *Blood cancer journal*, vol. 10, no. 6, pp. 71, DOI:10.1038/s41408-020-0338-x
- Valgimigli, M., Bueno, H., Byrne, R.A., Collet, J.P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Lesiak, M., Neumann, F.J., Petricevic, M., Roffi, M., Siontis, G.C.M., Stefanini, G.G., Windecker, S., Windecker, S. and Members, E.S.C., 2018, '2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS', *European Heart Journal*, 39(3), pp.213–260. DOI: 10.1093/eurheartj/ehx419

- Veronese, N., Ragusa, F.S., Maggi, S., Witard, O.C., Smith, L., Dominguez, L.J., Barbagallo, M., Isanejad, M. & Prokopenko, K., 2025, 'Effect of the Mediterranean diet on incidence of heart failure in European countries: a systematic review and meta-analysis of cohort studies', *European Journal of Clinical Nutrition*, vol. 79, pp. 195–199. <https://doi.org/10.1038/s41430-024-01519-4>
- Wallentin, L., 2009, 'P2Y12 inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use', *European Heart Journal*, vol. 30, no. 16, pp. 1964–1977, DOI:10.1093/eurheartj/ehp296
- Wei, P., Wang, X., Fu, Q., & Cao, B., 2024, 'Progress in the clinical effects and adverse reactions of ticagrelor', *Thrombosis Journal*, vol. 22, no. 1, pp. 8, DOI:10.1186/s12959-023-00559-3
- Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J. & Lisheng, L., 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *The Lancet*, 364(9438), pp.937–952. [https://doi.org/10.1016/S0140-6736\(04\)17018-9](https://doi.org/10.1016/S0140-6736(04)17018-9)
- Zahra, P.T., 2023, 'Hubungan Skor Atherosclerotic Cardiovascular Disease (ASVCD Score) Dengan Derajat Stenosis Berdasarkan One Vessel, Two Vessel, Three Vessel Disease Score Angiografi: Studi Observasional Analitik di Rumah Sakit Islam Sultan Agung Semarang Pada Pasien Jantung Koroner', Thesis, Fakultas Kedokteran Universitas Islam Sultan Agung, Semarang.
- Zaid, A. N., Al Ramahi, R., Bustami, R., Mousa, A., & Khasawneh, S. 2015, 'Comparative fasting bioavailability of two clopidogrel formulations in healthy Mediterranean volunteers: an in vitro–in vivo correlation', *Drug Design, Development and Therapy*, pp. 2359-2365.